Eiger: Strong Hep D Data, Likely Approval, Cash Strapped

Eiger Biopharmaceuticals has very robust data from its hepatitis D virus trial.

Its successful phase 3 in ultrarare HGPS indicates almost assured approval.

However, the company is cash-strapped, and even the new revenue stream may not be adequate.

https://seekingalpha.com/article/4224506-eiger-biopharmaceuticals-strong-hdv-data-almost-assured-approval-hgps-cash-strapped